1-Stearoyl-2-Arachidonoyl-d11-sn-glycero-3-PC
(Synonyms: 18:0/20:4-d11-PC, PC(18:0/20:4-d11), SAPC-d11, 1-Stearoyl-2-Arachidonoyl-d11-sn-glycero-3-Phosphatidylcholine, 1-Stearoyl-2-Arachidonoyl-d11-sn-glycero-3-Phosphocholine) 目录号 : GC46494
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
1-Stearoyl-2-arachidonoyl-d11-sn-glycero-3-PC (SAPC-d11) is intended for use as an internal standard for the quantification of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by GC- or LC-MS. SAPC is a phospholipid containing stearic acid and arachidonic acid at the sn-1 and sn-2 positions, respectively. It is a component of LDL and has been found in human stenotic aortic valves and atherosclerotic plaques.1,2 Levels of SAPC are increased in the subepithelial invasive region compared to the superficial region of tumor tissue samples from patients with superficial-type pharyngeal squamous cell carcinoma.3 SAPC unilamellar vesicles have been used as substrates to quantify the activity of secretory phospholipase A2 (sPLA2) in the presence or absence of inhibitors.4 SAPC has also been used in the formation of lipid bilayers to study the effects of lipid composition on bilayer phase transitions.5
1.Milne, G.L., Seal, J.R., Havrilla, C.M., et al.Identification and analysis of products formed from phospholipids in the free radical oxidation of human low density lipoproteinsJ. Lipid Res.46(2)307-319(2005) 2.Lehti, S., KÄkelÄ, R., HÖrkkÖ, S., et al.Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valvesPLoS One8(6)e65810(2013) 3.Ishikawa, S., Tateya, I., Hayasaka, T., et al.The distribution of phosphatidylcholine species in superficial-type pharyngeal carcinomaBiomed. Res. Int.5387913(2017) 4.Schebb, N.H., Falck, D., Faber, H., et al.Fast method for monitoring phospholipase A2 activity by liquid chromatography-electrospray ionization mass spectrometryJ. Chromatogr. A1216(27)5249-5255(2009) 5.Tada, K., Goto, M., Tamai, N., et al.Pressure effect on the bilayer phase transition of asymmetric lipids with an unsaturated acyl chainAnn. N.Y. Acad. Sci.1189(1)77-85(2010)
| Cas No. | N/A | SDF | |
| 别名 | 18:0/20:4-d11-PC, PC(18:0/20:4-d11), SAPC-d11, 1-Stearoyl-2-Arachidonoyl-d11-sn-glycero-3-Phosphatidylcholine, 1-Stearoyl-2-Arachidonoyl-d11-sn-glycero-3-Phosphocholine | ||
| Canonical SMILES | O=C(CCCCCCCCCCCCCCCCC)OC[C@@H](OC(CCC/C=C\C/C=C\C/C=C\C/C=C\C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)COP([O-])(OCC[N+](C)(C)C)=O | ||
| 分子式 | C46H73D11NO8P | 分子量 | 821.2 |
| 溶解度 | Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:2): 0.3 mg/ml | 储存条件 | Store at -80°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2177 mL | 6.0887 mL | 12.1773 mL |
| 5 mM | 0.2435 mL | 1.2177 mL | 2.4355 mL |
| 10 mM | 0.1218 mL | 0.6089 mL | 1.2177 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet